Subacute inhalation exposure of rats to 1,6-hexamethylene diisocyanate with recovery period.
In this subacute inhalation toxicity study of 1,6-hexamethylene diisocyanate (HDI), groups of 10 male and 10 female Sprague-Dawley rats were exposed to 0, 0.005, 0.0175, or 0.150 ppm HDI vapor, 5 h/day, 5 days/wk for 15 exposure days and included animals sacrificed 2 wk postexposure. The purpose was to characterize the HDI-induced effects and their reversibility, and to determine a no-observed-adverse-effect level (NOAEL). No compound-related effects were found for body weights, clinical chemistry, urinalysis, hematology, and organ weights. Thus, no evidence of systemic toxicity was found in this study. The exposure-related findings were restricted to the portal of entry, the respiratory tract. Transient signs of sensory irritation were observed after the daily exposure periods, but the principal findings were the histopathologic changes of the nasal epithelium. Generally, an anterior to posterior gradient of incidence and severity was found, and the changes were characterized as acanthosis, erosion, hyperkeratosis, epithelial cell hyperplasia, chronic active inflammation, squamous metaplasia, ulceration, transitional epithelial cell degeneration, goblet-cell hyperplasia, and degeneration of the olfactory epithelium. Varying degrees of concordance between exposure concentration and incidence and/or severity of the histopathologic changes were found. During a 2-wk recovery period, a tendency toward recovery was evident for tissue changes in the nasal cavity. A NOAEL of 0.0175 ppm HDI was determined.
Shiotsuka
Ronald N
RN
Bayer CropScience LP, Toxicology, Stilwell, Kansas, USA. ron.shiotsuka@bayercropscience.com
Stuart
Barry P
BP
Sangha
Ghona K
GK
Sturdivant
David W
DW
Hoss
Herbert
H
D000280:Administration, Inhalation; D000395:Air Pollutants, Occupational / Q000633:toxicity*; D000818:Animals; D003485:Cyanates / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019570:Inhalation Exposure; D017953:Isocyanates; D008297:Male; D009296:Nasal Cavity / Q000187:drug effects* / Q000473:pathology; D009297:Nasal Mucosa / Q000187:drug effects* / Q000473:pathology; D019055:No-Observed-Adverse-Effect Level; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D014420:Turbinates / Q000187:drug effects / Q000473:pathology; D028761:Withholding Treatment
D000395:Air Pollutants, Occupational; D003485:Cyanates; D017953:Isocyanates; C015262:1,6-hexamethylene diisocyanate